<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02260154</url>
  </required_header>
  <id_info>
    <org_study_id>MEBE5002</org_study_id>
    <nct_id>NCT02260154</nct_id>
  </id_info>
  <brief_title>Effectiveness of Duspatalin® in Patients With Post-cholecystectomy Gastrointestinal Spasm</brief_title>
  <acronym>ODYSSEY</acronym>
  <official_title>Effectiveness of Duspatalin® (Mebeverine Hydrochloride) 200 mg b.i.d. in Patients With Post-cholecystectomy Gastrointestinal Spasm: a Post Marketing Observational Program in the Russian Federation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Data Matrix</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, multicenter, non-comparative, observational program designed to assess the
      effectiveness of a 2-6 weeks treatment with Duspatalin® 200mg BID and changes in quality of
      life in patients with post-cholecystectomy gastro-intestinal spasms
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">October 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of &quot;responders&quot; to Duspatalin® therapy</measure>
    <time_frame>2 weeks</time_frame>
    <description>Patients indicating being `symptom-free` or `markedly improved`on Global Patient Assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of &quot;responders&quot; to Duspatalin® therapy</measure>
    <time_frame>Up to 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in abdominal pain</measure>
    <time_frame>Baseline, 2 weeks and up to 6 weeks</time_frame>
    <description>Measured by 11-point numerical rating scale and patient`s assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in dyspepsia symptoms</measure>
    <time_frame>Baseline, 2 weeks and up to 6 weeks</time_frame>
    <description>Measured by 11-point numerical rating scale and patient`s assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in stool habits and percentage of patients with abnormal stool form</measure>
    <time_frame>Baseline, 2 weeks and up to 6 weeks</time_frame>
    <description>Stool form is measured by Bristol Stool Form scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in quality of life</measure>
    <time_frame>Baseline, 2 weeks and up to 6 weeks</time_frame>
    <description>Gastrointestinal Quality of Life Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjects characteristics</measure>
    <time_frame>Baseline</time_frame>
    <description>Demographics data, relevant medical history and available laboratory data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economic data</measure>
    <time_frame>Baseline, up to 6 weeks</time_frame>
    <description>Relevant concomitant medication, number of visits to clinic and days missed from work for currently employed subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for continuing treatment beyond 2 weeks</measure>
    <time_frame>2 weeks</time_frame>
    <description>List and rate of reasons</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">220</enrollment>
  <condition>Post-cholecystectomy Gastrointestinal Spasms</condition>
  <arm_group>
    <arm_group_label>Post-cholecystectomy gastrointestinal spasms</arm_group_label>
    <description>Adult subjects suffering from post-cholecystectomy gastrointestinal spasms not requiring surgical treatment prescribed Duspatalin® 200 mg twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mebeverine</intervention_name>
    <description>Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed</description>
    <arm_group_label>Post-cholecystectomy gastrointestinal spasms</arm_group_label>
    <other_name>Duspatalin</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 years to 65 years;

          -  Patients suffering from post-cholecystectomy GI-spasms in the last 3 months with
             symptom onset at least 6 months prior to inclusion and not requiring surgical
             treatment;

          -  Laparoscopic cholecystectomy between 6 months to 5 years before enrollment;

          -  Patients having been prescribed Duspatalin® (mebeverine) 200 mg BID (bis in die =
             twice a day) in accordance with approved local label;

          -  Patient's written authorization to provide data for the program

        Exclusion Criteria:

          -  General and specific contraindications to Duspatalin® treatment according to the local
             label;

          -  Planned Endoscopic Retrograde Cholangiopancreatography (ERCP) and/or surgical
             treatment;

          -  Being currently treated or having been treated with Duspatalin® within the 6 weeks
             prior to entering the program;

          -  Pregnancy or lactation;

          -  Other conditions that make patient participation impossible (by investigator
             judgment);

          -  Previous enrollment in the present program;

          -  Treatment with other antispasmodics, pain-medication (Nonsteroidal anti-inflammatory
             drugs (NSAIDs), tramadol, etc.) within 2 weeks prior to inclusion into the
             observational study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tatiana Vladimirova, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility ID ORG-001035</name>
      <address>
        <city>Chita</city>
        <zip>672090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Institution &quot; Irkutsk State Medical Academy of postgraduate education&quot;</name>
      <address>
        <city>Irkutsk</city>
        <zip>664049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-001038</name>
      <address>
        <city>Izhevsk</city>
        <zip>426034</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-001033</name>
      <address>
        <city>Kazan</city>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-governmental Healthcare Institution &quot;Road Clinical Hospital on the station Khabarovsk-1 OSS &quot;Russian Railways&quot;</name>
      <address>
        <city>Khabarovsk</city>
        <zip>680022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-001034</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research facility ID ORG-001039</name>
      <address>
        <city>Moscow</city>
        <zip>111123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution &quot;Outpatient hospital №1&quot; Administration of the President of the Russian Federation</name>
      <address>
        <city>Moscow</city>
        <zip>119002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Institution &quot;Pirogov Russian National Research Medical University&quot;, on the base of State Budget Institution of Health Care of Moscow &quot;City Clinical Hospital №31&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>119415</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Institution &quot;Russian Medical Academy of Postgraduate Studies</name>
      <address>
        <city>Moscow</city>
        <zip>123836</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Institution of Health Care of Moscow region &quot; MF Vladimirsky Moscow Region Scientific Research Clinical University&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-001024</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Institution &quot;Nizhny Novgorod Regional Clinical Hospital n.a. Semashko&quot;</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Institution &quot;Novosibirsk State Medical University&quot;</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-000903</name>
      <address>
        <city>Omsk</city>
        <zip>644043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution Hospital of the Pushchino Scientific Center of the Russian Academy of Sciences</name>
      <address>
        <city>Pushino</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-001036</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Federal State Budget Institution All-Russian Center of Emergency and Radiation Medicine of EMERCOM of Russia</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budget Institution &quot;North-Western State Medical University named after I.I. Mechnikov&quot;, on the base of State Budget Institution &quot;Sity Clinical Hospital #26&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility ID ORG-001037</name>
      <address>
        <city>Saransk</city>
        <zip>430005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #40</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>, 620102</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2014</study_first_submitted>
  <study_first_submitted_qc>October 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2014</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duspatalin</keyword>
  <keyword>mebeverine</keyword>
  <keyword>cholecystectomy</keyword>
  <keyword>gastrointestinal spasm</keyword>
  <keyword>abdominal pain</keyword>
  <keyword>dyspepsia</keyword>
  <keyword>antispasmodics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spasm</mesh_term>
    <mesh_term>Muscle Cramp</mesh_term>
    <mesh_term>Postcholecystectomy Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mebeverine</mesh_term>
    <mesh_term>Alverine</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 5, 2017</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

